Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed)

The summary for the Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to further validate promising EEG and eye tracking measures that showed promising performance in the recently-completed Autism Biomarkers Consortium for Clinical Trials (ABC-CT) study. The intent of the FOA is to qualify a set of measures that can be used as biomarkers to reduce heterogeneity, and/or as sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) clinical trials. The FOA will support a multi-site consortium to conduct a study with three primary aims to replicate and extend previous characterization of the most promising EEG and eye-tracking measures, incorporating suggestions and guidance from the FDA Biomarkers Qualification Program (BQP). A key goal of the Consortium project is to provide a community resource for broad sharing of all data generated including processed/analyzed data, with rapid and timely deposition of data into the National Database for Autism Research (NDAR). All data generated in this project are expected to be deposited in NDAR and will be accessible for use by all qualified investigators. In addition, blood (DNA) samples are expected to be deposited in the NIMH Repository and Genomics Resource for future research use. The Consortium project will assess the following: (1) whether eye-tracking, EEG paradigms, or a combination of the two, have potential utility as stratification biomarkers and/or as sensitive and reliable measures of change in ASD clinical trials; (2) the relationship (correlation) of validated clinical measures (including measures of social impairment) to eye tracking or EEG paradigms; and (3) the feasibility of collecting the same biomarker measures in a younger cohort.

Federal Grant Title:	Limited Competition: Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-20-325
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.173, 93.242, 93.853, 93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 23rd, 2019
Original Application Deadline:	December 23rd, 2019
Posted Date:	November 6th, 2019
Creation Date:	November 6th, 2019
Archive Date:	January 28th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	November 7th, 2019

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See the funding announcement for the eligibility details
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-325.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Medical Rehabilitation Research Resource (P50 Clinical Trial Optional); • Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Tr...; • BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Centr...; • NIDCD Patient-Oriented Research Grant (R21); • Cell Lineage and Developmental Studies in Hearing and Balance; • Structural Analyses of the Ligand-Binding Properties of Taste and Smell Receptors
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...